Alan Evans

Biospective Inc. is a specialty Contract Research Organization (CRO) with particular strengths in CNS diseases and disorders, including Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, ALS, Schizophrenia, and Depression. Our unique, state-of-the-art technologies and world-class scientific pre-clinical and clinical expertise accelerates the drug discovery timeline. Biospective provides industry-leading services in several cores areas: animal models and behavioral assays; animal imaging (NIGHTWING™ Platform), histology, and quantitative IHC (PERMITS™ Platform); and human MRI, fMRI, PET, and SPECT imaging (PIANO™ Platform). These platforms represent some of Biospective’s fully-automated, unbiased, and high-throughput technologies that provide sponsors with an unparalleled ability to assess the efficacy of their novel therapeutic agents throughout preclinical and clinical drug development.